Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2025-05-14 Regulatory Filings
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
FDA meddelar PDUFA-datum för Xspray Pharmas kompletterade ansökan för Dasynoc®
Regulatory Filings Classification · 100% confidence The document is a short press release (3108 characters) announcing that the FDA has confirmed receipt of a supplemental NDA for Dasynoc® and set a PDUFA date (October 7, 2025). It contains key highlights, quotes from the CEO, and contact information for Investor Relations. Crucially, the end of the document lists an 'Bifogade filer' (Attached files) section pointing to a PDF document, which aligns with the 'MENU VS MEAL' rule. This indicates the text itself is an announcement about a regulatory event/filing, rather than the comprehensive report itself. Since it is a specific regulatory update concerning a drug application status (NDA/PDUFA date), it is not a standard financial report (10-K, IR, ER). It is a specific regulatory announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for non-standard, specific regulatory news releases that don't fit other specific financial/corporate action codes, although 'LTR' (Legal Proceedings Report) might be considered if the CRL was strictly legal, but PDUFA dates relate to application status. RNS serves as the best fit for general regulatory news updates not covered elsewhere.
2025-05-14 Swedish
FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding the FDA setting a PDUFA date for Xspray Pharma's resubmitted NDA for Dasynoc®. It contains key updates, quotes from the CEO, and contact information. Crucially, the document ends with an 'Attachments' section linking to a PDF of the announcement itself. Given the short length (3033 chars) and the nature of announcing a regulatory event rather than being the full regulatory filing (like a 10-K or IR), this fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a regulatory milestone (PDUFA date), and it is presented as a brief news release with an attachment, RPA is the most appropriate classification, as it announces the publication of this specific news/update.
2025-05-14 English
Kommuniké från årsstämma i Xspray Pharma AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Kommuniké från årsstämma i Xspray Pharma AB (publ)' which translates to 'Communiqué from the Annual General Meeting (AGM) of Xspray Pharma AB (publ)'. The text details decisions made at the AGM on May 13, 2025, including approval of the 2024 accounts, discharge of the board, election of board members and auditor, decisions on remuneration, and approval of incentive programs (LTIP 2025). These contents directly correspond to the definition of AGM Information. Although it is a communiqué summarizing the meeting, the content is the core output of the AGM, making AGM-R the most appropriate classification over a general RPA or RNS.
2025-05-13 Swedish
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Bulletin from the annual general meeting of Xspray Pharma AB (publ)" and details resolutions passed at the AGM regarding financial statements adoption, board elections, remuneration, and incentive programs. This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4788 chars) is substantial enough to be the primary report/bulletin, not just a short announcement of publication.
2025-05-13 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period January - March 2025. It contains comprehensive financial data, including income statements, cash flow summaries, key performance indicators (Nyckeltal), and detailed management commentary (VD har ordet) regarding business operations, product development, and market outlook. As it provides substantive financial results for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2025
2025-05-07 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report' and covers the period January–March 2025. It contains comprehensive financial data, including key figures, income statements, cash flow analysis, and management commentary on business performance and outlook. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-05-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.